PDX Core

PDX核心

• 批准号: 10005284
• 负责人: Shunqiang Li
• 金额: $ 2.01万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10005284
• 关键词: Antineoplastic Agents; Back; Bioinformatics; Biological Markers; Breast; Characteristics; Clinical Data; Clinical Research; Collection; Colorectal; Colorectal Cancer; Data; Databases; Development; Drug Modelings; Ensure; Evaluation; Feedback; Funding; Goals; Heterogeneity; Human; Infrastructure; Institutes; Link; Lung; Lymphoma; Malignant Neoplasms; Methodology; Modeling; Molecular Cloning; Molecular Profiling; Monitor; Mus; Mutation; Pancreas; Patients; Quality Control; Research; Research Personnel; Research Project Grants; Safety; Sampling; Short Tandem Repeat; Solid Neoplasm; Structure; Testing; Tissue Banks; Universities; Washington; base; cancer subtypes; cancer type; capsule; drug testing; exome sequencing; genomic profiles; implantation; improved; medical schools; member; pathogen; programs; proteogenomics; rare cancer; sarcoma; screening; subcutaneous; success; tissue registry; tool; transcriptome sequencing; translational study; tumor

The PDX Core is the epicenter of the WU-PDTC as it will be responsible for the development, organization, characterization, storage, and dissemination of high quality pathogen free PDX models for research projects investigating anticancer agents, within and outside of WU-PDTC. The PDX Core builds on outstanding existing infrastructure and expertise at Washington University School of Medicine (WUSM). The Human and Mouse Linked Evaluation of Tumors (HAMLET) PDX Core at the Institute of Clinical and Translational Study (ICTS) and the Solid Tumor Tissue Bank and Registry (STTBR) led by Drs. Li and Fields, respecitvely, have a proven record of success in generating PDX models from a wide variety of cancers and in utilizing these models for drug testing. Between these programs, we have already generated over 449 PDX models across more than 12 cancer types, from the most common cancers, such as breast, lung, and colorectal, to rare cancers, such as sarcomas and lymphomas. These existing models will become part of the new WU-PDTC, where about 1000 new PDX models will be developed and added to this collection. The new PDX models will further enhance our capability to support ongoing projects and open new opportunities for research in rare cancer types. Taking advantage of the strong proteogenomic capability within the proposed WU-PDTC and WUSM, we will expand the characterization of these PDX models to include both whole exome sequencing and RNA-Seq, providing investigators with a more comprehensive picture of the mutational profiles, the molecular signatures, clonal structures, and heterogeneities of the models to help with cancer sub-typing and target selection. Besides research projects at WU-PDTC, PDX models in the PDX Core collection will also be shared with other PDTCs and made broadly available to authorized non-network investigators. Furthermore, the PDX Core will study new approahes to improve the take rate, fidelity, and characterization of PDX models. The large patient base and exceptionally strong institutional backing, including matching funds, will additionally ensure that these goals are achievable.

PDX核心是WU-PDTC的中心，因为它将负责开发，组织， 为研究项目表征、储存和传播高质量无病原体PDX模型 在WU-PDTC内部和外部研究抗癌药物。PDX Core基于现有的优秀 华盛顿大学医学院（WUSM）的基础设施和专业知识。人和小鼠 临床和转化研究所（ICTS）的肿瘤关联评价（哈姆雷特）PDX核心 李博士和菲尔兹博士分别领导的实体瘤组织库和登记处（STTBR）， 成功地从各种癌症中生成PDX模型并利用这些模型用于 药检在这些项目中，我们已经在超过12个项目中生成了超过449个PDX模型。 癌症类型，从最常见的癌症，如乳腺癌，肺癌和结肠直肠癌，到罕见的癌症，如 肉瘤和淋巴瘤。这些现有的模型将成为新的WU-PDTC的一部分，其中约1000 将开发新的PDX模型并添加到该系列中。新的PDX车型将进一步增强我们的 支持正在进行的项目，并为罕见癌症类型的研究开辟新的机会。以 利用拟议的WU-PDTC和WUSM中强大的蛋白质基因组学能力，我们将扩大 这些PDX模型的表征包括全外显子组测序和RNA-Seq， 研究人员对突变谱、分子特征、克隆 结构和模型的异质性，以帮助癌症亚型和靶点选择。除了 WU-PDTC的研究项目、PDX Core集合中的PDX模型也将与其他PDTC共享 并广泛提供给授权的非网络调查人员。此外，PDX核心将研究 改进PDX模型的拍摄率、保真度和特征化的新方法。庞大的患者基数 特别强大的机构支持，包括配套资金，将进一步确保这些 目标是可以实现的。